Acute Respiratory Distress Syndrome (ARDS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Acute Respiratory Distress Syndrome (ARDS) Emerging Therapy and TPP Insights

Thelansis’s “Acute Respiratory Distress Syndrome (ARDS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute respiratory distress syndrome (ARDS) is a catastrophic, life-threatening inflammatory lung injury characterized by the acute onset of non-cardiogenic pulmonary edema, driven by the profound disruption of the alveolar-capillary membrane barrier. This rapid increase in permeability leads to the histological hallmark of diffuse alveolar damage (DAD), hyaline membrane formation, and refractory hypoxemic respiratory failure. It manifests as a severe complication of direct pulmonary insults (such as severe pneumonia or aspiration) or indirect systemic inflammatory cascades (most notably sepsis or severe trauma). Diagnosis and severity stratification are strictly governed by the Berlin Definition, which categorizes ARDS as mild, moderate, or severe based on the degree of hypoxemia (PaO2/FiO2 ratio) in the presence of bilateral radiographic opacities not fully explained by cardiac failure or fluid overload. Because there are currently no approved targeted pharmacotherapies to halt the underlying inflammatory cascade, management is exclusively supportive. The standard of care mandates highly protocolized lung-protective mechanical ventilation—utilizing low tidal volumes and optimized positive end-expiratory pressure (PEEP) to minimize ventilator-induced lung injury (VILI)—alongside conservative fluid management. For patients with severe, refractory hypoxemia, modern critical care relies heavily on advanced rescue interventions, including early extended prone positioning, neuromuscular blockade, and venovenous extracorporeal membrane oxygenation (VV-ECMO).

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Acute Respiratory Distress Syndrome (ARDS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025